Jamois C - Search Results

1

Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas.

Zhai J, Qin Y, Zhu J, Song Y, Shen Z, Du X, Jamois C, Brewster M, Shi Y, Shi J. Zhai J, et al. Among authors: jamois c. Br J Clin Pharmacol. 2017 Jul;83(7):1446-1456. doi: 10.1111/bcp.13232. Epub 2017 Feb 14. Br J Clin Pharmacol. 2017. PMID: 28072473 Free PMC article. Clinical Trial.

2

Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1.

Sánchez J, Nicolini V, Fahrni L, Waldhauer I, Walz AC, Jamois C, Fowler S, Simon S, Klein C, Umaña P, Friberg LE, Frances N. Sánchez J, et al. Among authors: jamois c. AAPS J. 2023 Apr 1;25(3):34. doi: 10.1208/s12248-023-00802-9. AAPS J. 2023. PMID: 37002450 No abstract available.

3

Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.

Sanwald-Ducray P, Liogier D'ardhuy X, Jamois C, Banken L. Sanwald-Ducray P, et al. Among authors: jamois c. Clin Pharmacol Ther. 2010 Aug;88(2):197-203. doi: 10.1038/clpt.2009.259. Epub 2010 Mar 24. Clin Pharmacol Ther. 2010. PMID: 20336066 Clinical Trial.

4

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.

Jamois C, Gibiansky E, Gibiansky L, Buchheit V, Sahin D, Cartron G, Marcus R, Hiddemann W, Seymour JF, Strefford JC, Hargreaves CE, Meneses-Lorente G, Frey N, Fingerle-Rowson G. Jamois C, et al. Br J Clin Pharmacol. 2019 Jul;85(7):1495-1506. doi: 10.1111/bcp.13920. Epub 2019 May 17. Br J Clin Pharmacol. 2019. PMID: 30866056 Free PMC article. Clinical Trial.

5

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.

Gibiansky E, Gibiansky L, Buchheit V, Frey N, Brewster M, Fingerle-Rowson G, Jamois C. Gibiansky E, et al. Among authors: jamois c. Br J Clin Pharmacol. 2019 Sep;85(9):1935-1945. doi: 10.1111/bcp.13974. Epub 2019 Jul 12. Br J Clin Pharmacol. 2019. PMID: 31050355 Free PMC article. Clinical Trial.

6

Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.

Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N, Reed EF, Tremblay S, Zachary AA, Vo AA, Formica R, Schindler T, Tran H, Looney C, Jamois C, Green C, Morimoto A, Rajwanshi R, Schroeder A, Cascino MD, Brunetta P, Borie D. Redfield RR, et al. Among authors: jamois c. Am J Transplant. 2019 Nov;19(11):3035-3045. doi: 10.1111/ajt.15514. Epub 2019 Jul 23. Am J Transplant. 2019. PMID: 31257724 Free PMC article. Clinical Trial.

7

Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B-Cell Hematological Malignancies.

Jamois C, Gibiansky E, Gibiansky L, Chavanne C, Morcos PN, McIntyre C, Barrett M, Lundberg L, Zharkov A, Boehnke A, Frey N. Jamois C, et al. Clin Pharmacol Ther. 2021 Nov;110(5):1261-1272. doi: 10.1002/cpt.2308. Epub 2021 Jun 26. Clin Pharmacol Ther. 2021. PMID: 34041738 Free PMC article. Clinical Trial.

8

Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.

Jamois C, Smith P, Morrison R, Riek M, Patel A, Schmitt C, Morcos PN, Zhang X. Jamois C, et al. Addict Biol. 2009 Jul;14(3):321-7. doi: 10.1111/j.1369-1600.2009.00158.x. Addict Biol. 2009. PMID: 19523046

9

The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects.

Sanwald-Ducray P, Jamois C, Banken L. Sanwald-Ducray P, et al. Among authors: jamois c. J Cardiovasc Pharmacol. 2014 Feb;63(2):152-7. doi: 10.1097/FJC.0000000000000033. J Cardiovasc Pharmacol. 2014. PMID: 24157957 Clinical Trial.

10

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL.

Gibiansky E, Gibiansky L, Carlile DJ, Jamois C, Buchheit V, Frey N. Gibiansky E, et al. Among authors: jamois c. CPT Pharmacometrics Syst Pharmacol. 2014 Oct 29;3(10):e144. doi: 10.1038/psp.2014.42. CPT Pharmacometrics Syst Pharmacol. 2014. PMID: 25353187 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters